CD19 CAR T Therapy Tested in Refractory Rheumatoid Arthritis

• September 8, 2026

Does TYK2/JAK1 Show Potential in Inflammatory Diseases?

Investigational inhibitor was not associated with treatment-related serious adverse events and produced biomarker changes consistent with pathway inhibition in healthy volunteers.

• by Andrea Surnit

• July 6, 2026

• 3 min

Predicting anti-CCP positivity and early rheumatoid arthritis onset from routine laboratory parameters: a SHAP-explained machine learning pipeline

• by Juan Wang, Jiaqing Chen, Kaiwen Wang

• June 29, 2026

Healthcare utilization and costs in patients with rheumatoid arthritis using biologics or tofacitinib: a nationwide, population-based study

• by Yen-Ju Chen, Wei-Li Ho, Hsian-Min Chen, Yi-Ming Chen, Hsin-Hua Chen

• June 22, 2026